Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 773 shares, a decrease of 85.7% from the July 30th total of 5,398 shares. Based on an average daily volume of 190 shares, the short-interest ratio is presently 4.1 days.
Sunshine Biopharma Stock Down 0.5%
NASDAQ:SBFMW traded down $0.00 during trading hours on Thursday, hitting $0.04. The company had a trading volume of 1,650 shares, compared to its average volume of 14,443. Sunshine Biopharma has a 1 year low of $0.02 and a 1 year high of $0.65. The company has a 50-day moving average of $0.04 and a 200 day moving average of $0.09.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
See Also
- Five stocks we like better than Sunshine Biopharma
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
